arrow
C

Carla Tortorella

S. Camillo-Forlanini Hospital
H指数:45
被引数:6,550

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical phenotype and treatment response in AQP4-IgG-positive NMOSD and MOGAD: insights from the Italian I-MS&RD registry

AQP4-IgG阳性NMOSD和MOGAD的临床表型及治疗反应:来自意大利I-MS&RD登记研究的见解

2026-10-160
PRE
Use of MRI in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease — MAGNIMS consensus recommendations

MRI在视神经脊髓炎谱系障碍和髓鞘少突胶质细胞糖蛋白抗体相关疾病中的应用——MAGNIMS共识建议

2026-09-280
PRE
Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study)

评估接受不同治疗方案序列治疗的视神经脊髓炎患者队列中长期严重不良事件风险的概况:意大利视神经脊髓炎及相关疾病登记研究(I-MS&RD)(ProSA研究)结果

2026-07-040
PRE
From Marginal to Central: Marginal Zone-like B Cells as Critical Targets in Cladribine-Treated Multiple Sclerosis

从边缘到中心:边缘区样B细胞作为克拉屈滨治疗多发性硬化的关键靶点

2026-06-180
OAAI
HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMS

HerMeS:一项基于注册研究的HERCULES标准评估,用于识别非复发型SPMS

2026-03-090
OAAI
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study

真实世界中多发性硬化患者使用克拉屈滨片的经验:一项多中心意大利研究的有效性数据

2025-12-260
OA
Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies

多发性硬化患者在接受疾病修饰疗法时,对COVID-19疫苗的Th1特异性反应与SARS-CoV-2突破性感染之间关联性极低。

2025-10-300
OAAI
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty

真实世界中奥法鲁单抗治疗复发型多发性硬化24个月的效果:疗效、安全性及虚弱症的影响

2025-09-190
OAAI
Epilepsy in MS and its association with cognitive and psychological burden

多发性硬化中的癫痫及其与认知和心理负担的关联

2025-07-310
OA
Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies
2025-02-011
PRE
Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination
2024-08-190
OAAI
Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project
2024-08-020
OAAI
Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis
2024-05-231
OAAI
Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience

在MS中使用那他珠单抗治疗的不同方案中的治疗调节剂: 意大利的真实世界经验

2024-04-011
OAAI
Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria

在多发性硬化诊断标准中加入视神经

2024-01-0917
PRE
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study

在现实环境中评估口服药物对多发性硬化症的治疗反应: 一项MAGNIMS研究

2023-09-296
PRE